A Matched Molecular and Clinical Analysis of the Epithelioid Haemangioendothelioma Cohort in the Stafford Fox Rare Cancer Program and Contextual Literature Review

Background: Epithelioid haemangioendothelioma (EHE) is an ultra-rare malignant vascular tumour with a prevalence of 1 per 1,000,000. It is typically molecularly characterised by a WWTR1::CAMTA1 gene fusion in approximately 90% of cases, or a YAP1::TFE3 gene fusion in approximately 10% of cases. EHE cases are typically refractory to therapies, and no anticancer agents are reimbursed for EHE in Australia. Methods: We report a cohort of nine EHE cases with comprehensive histologic and molecular profiling from the Walter and Eliza Hall Institute of Medical Research Stafford Fox Rare Cancer Program (WEHI-SFRCP) collated via nation-wide referral to the Australian Rare Cancer (ARC) Portal. The diagnoses of EHE were confirmed by histopathological and immunohistochemical (IHC) examination. Molecular profiling was performed using the TruSight Oncology 500 assay, the TruSight RNA fusion panel, whole genome sequencing (WGS), or whole exome sequencing (WES). Results: Molecular analysis of RNA, DNA or both was possible in seven of nine cases. The WWTR1::CAMTA1 fusion was identified in five cases. The YAP1::TFE3 fusion was identified in one case, demonstrating unique morphology compared to cases with the more common WWTR1::CAMTA1 fusion. All tumours expressed typical endothelial markers CD31, ERG, and CD34 and were negative for pan-cytokeratin. Cases with a WWTR1::CAMTA1 fusion displayed high expression of CAMTA1 and the single case with a YAP1::TFE3 fusion displayed high expression of TFE3. Survival was highly variable and unrelated to molecular profile. Conclusions: This cohort of EHE cases provides molecular and histopathological characterisation and matching clinical information that emphasises the molecular patterns and variable clinical outcomes and adds to our knowledge of this ultra-rare cancer. Such information from multiple studies will advance our understanding, potentially improving treatment options.

[1]  S. Si,et al.  Case report: Successful treatment with the combined therapy of interferon-alpha 2b and anlotinib in a patient with advanced hepatic epithelioid hemangioendothelioma , 2022, Frontiers in Medicine.

[2]  H. Yamakawa,et al.  Successful surgical treatment of epithelioid hemangioendothelioma involving multiple liver lesions and bilateral lung nodules , 2022, Respiratory medicine case reports.

[3]  Yan Dong,et al.  Establishment and Validation of a Nomogram Prognostic Model for Epithelioid Hemangioendothelioma , 2022, Journal of oncology.

[4]  Lijiang Chen,et al.  Primary epithelioid hemangioendothelioma of the eyelid: A case report , 2022, Oncology letters.

[5]  Shuting He,et al.  Epithelioid Hemangioendothelioma: Incidence, Mortality, Prognostic Factors, and Survival Analysis Using the Surveillance, Epidemiology, and End Results Database , 2022, Journal of oncology.

[6]  Y. Seto,et al.  Subcutaneous axillary primary epithelioid hemangioendothelioma: report of a rare case , 2022, Surgical Case Reports.

[7]  A. Gingras,et al.  TAZ/YAP fusion proteins: mechanistic insights and therapeutic opportunities. , 2022, Trends in cancer.

[8]  S. Si,et al.  Sirolimus combined with interferon-alpha 2b therapy for giant hepatic epithelioid hemangioendothelioma: a case report , 2022, Frontiers in Oncology.

[9]  A. Erfani,et al.  Primary malignant epithelioid hemangioendothelioma of the pleura: A review and report of a novel case , 2022, Clinical case reports.

[10]  Kwan Chang Kim,et al.  Pulmonary Multinodular Epithelioid Hemangioendothelioma with Mixed Progression and Spontaneous Regression during a 7-Year Follow-Up: A Case Report and Review of Imaging Findings. , 2022, Journal of the Korean Society of Radiology.

[11]  S. Si,et al.  MRI appearances of hepatic epithelioid hemangioendothelioma: a retrospective study of 57 patients , 2022, Insights into Imaging.

[12]  D. Samuel,et al.  Advanced epithelioid hemangioendothelioma of the liver: could lenvatinib offer a bridge treatment to liver transplantation? , 2022, Therapeutic advances in medical oncology.

[13]  C. Qin,et al.  Rapid death due to pulmonary epithelioid haemangioendothelioma in several weeks: A case report , 2022, Open life sciences.

[14]  J. Lai,et al.  Cytologic features of hepatic YAP1‐TFE3 rearranged epithelioid hemangioendothelioma , 2021, Diagnostic Cytopathology.

[15]  H. Moch,et al.  YAP1-TFE3-fused hemangioendothelioma: a multi-institutional clinicopathologic study of 24 genetically-confirmed cases , 2021, Modern Pathology.

[16]  C. Fletcher,et al.  Loss of expression of YAP1 C-terminus as an ancillary marker for epithelioid hemangioendothelioma variant with YAP1-TFE3 fusion and other YAP1-related vascular neoplasms , 2021, Modern Pathology.

[17]  C. Antonescu,et al.  Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts , 2021, ESMO open.

[18]  K. Ganjoo,et al.  Management Strategies for Patients With Epithelioid Hemangioendothelioma , 2021, American journal of clinical oncology.

[19]  David M. Thomas,et al.  Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities , 2021, Cancer.

[20]  D. Rakheja,et al.  WWTR1(TAZ)-CAMTA1 reprograms endothelial cells to drive epithelioid hemangioendothelioma , 2021, Genes & development.

[21]  Robin L. Jones,et al.  Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature , 2021, Cancer medicine.

[22]  A. Caraceni,et al.  Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers Network , 2021, ESMO open.

[23]  S. Fröhling,et al.  Accurate and efficient detection of gene fusions from RNA sequencing data , 2021, Genome research.

[24]  Y. Yatabe,et al.  Clinicopathologic Characterization of Epithelioid Hemangioendothelioma in a Series of 62 Cases , 2021, The American journal of surgical pathology.

[25]  L. Jiao,et al.  Hepatic epithelioid hemangioendothelioma (HEHE)—rare vascular malignancy mimicking cholangiocarcinoma: a case report , 2021, Translational gastroenterology and hepatology.

[26]  Xiaoming Liu,et al.  dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs , 2020, Genome Medicine.

[27]  Justin Bedő,et al.  Unifying package managers, workflow engines, and containers: Computational reproducibility with BioNix , 2020, GigaScience.

[28]  L. Mariani,et al.  Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case‐series analysis within the Italian Rare Cancer Network , 2020, Cancer.

[29]  Patrick J. Paddison,et al.  Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis , 2020, Genes & development.

[30]  Jose Espejo Valle-Inclan,et al.  GRIDSS2: comprehensive characterisation of somatic structural variation using single breakend variants and structural variant phasing , 2021, Genome Biology.

[31]  F. Dane,et al.  VEGF-VEGFR pathway seems to be the best target in hepatic epithelioid hemangioendothelioma: A case series with review of the literature. , 2020, Current problems in cancer.

[32]  Rajiv M. Patel,et al.  Cutaneous soft tissue tumors: diagnostically disorienting epithelioid tumors that are not epithelial, and other perplexing mesenchymal lesions , 2019, Modern Pathology.

[33]  S. Sleijfer,et al.  Pan-cancer whole-genome analyses of metastatic solid tumours , 2019, Nature.

[34]  S. Millis,et al.  Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma , 2019, JAMA network open.

[35]  Narasimhan P. Agaram,et al.  Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets , 2019, Modern Pathology.

[36]  Robin L. Jones,et al.  The Role of Local Therapy in Multi-focal Epithelioid Haemangioendothelioma , 2019, AntiCancer Research.

[37]  S. Carlan,et al.  Epithelioid Hemangioendothelioma: A Rare Case of an Aggressive Vascular Malignancy , 2019, The American journal of case reports.

[38]  A. Gown,et al.  Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: a comparative, 2-laboratory study. , 2019, Human pathology.

[39]  Gerton Lunter,et al.  A unified haplotype-based method for accurate and comprehensive variant calling , 2018, Nature Biotechnology.

[40]  J. Furuse,et al.  Clinical characteristics of Japanese patients with epithelioid hemangioendothelioma: a multicenter retrospective study , 2018, BMC Cancer.

[41]  Chien‐Hung Yeh,et al.  FBXW7: a critical tumor suppressor of human cancers , 2018, Molecular Cancer.

[42]  Christopher T. Saunders,et al.  Strelka2: fast and accurate calling of germline and somatic variants , 2018, Nature Methods.

[43]  E. Cuppen,et al.  MutationalPatterns: comprehensive genome-wide analysis of mutational processes , 2017, bioRxiv.

[44]  Heng Li,et al.  Minimap2: pairwise alignment for nucleotide sequences , 2017, Bioinform..

[45]  M. Boerries,et al.  Epithelioid hemangioendotheliomas of the liver and lung in children and adolescents , 2017, Pediatric blood & cancer.

[46]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[47]  Eivind Hovig,et al.  Personal Cancer Genome Reporter: variant interpretation report for precision oncology , 2017, bioRxiv.

[48]  Verónica Rivas,et al.  G-Protein–Coupled Receptor Kinase 2 as a Potential Modulator of the Hallmarks of Cancer , 2017, Molecular Pharmacology.

[49]  Daniel L. Cameron,et al.  GRIDSS: sensitive and specific genomic rearrangement detection using positional de Bruijn graph assembly , 2017, bioRxiv.

[50]  Robin L. Jones,et al.  Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis , 2017, Acta oncologica.

[51]  L. Su,et al.  Interferon-alpha therapy for refractory kaposiform hemangioendothelioma: a single-center experience , 2016, Scientific Reports.

[52]  L. Doyle,et al.  Refinements in Sarcoma Classification in the Current 2013 World Health Organization Classification of Tumours of Soft Tissue and Bone. , 2016, Surgical oncology clinics of North America.

[53]  Måns Magnusson,et al.  MultiQC: summarize analysis results for multiple tools and samples in a single report , 2016, Bioinform..

[54]  V. Seshan,et al.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.

[55]  Xiaoyu Chen,et al.  Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications , 2016, Bioinform..

[56]  A. Lazar,et al.  Molecular characterization of epithelioid haemangioendotheliomas identifies novel WWTR1–CAMTA1 fusion variants , 2015, Histopathology.

[57]  O. Hofmann,et al.  VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research , 2016, Nucleic acids research.

[58]  G. Murray,et al.  The Hippo signal transduction pathway in soft tissue sarcomas. , 2015, Biochimica et biophysica acta.

[59]  Myke R. Green,et al.  Combination capecitabine and bevacizumab in the treatment of metastatic hepatic epithelioid hemangioendothelioma , 2015, Therapeutic advances in medical oncology.

[60]  M. Wachtel,et al.  Treatment of Hepatic Epithelioid Hemangioendothelioma: Finding Uses for Thalidomide in a New Era of Medicine , 2015, Case reports in gastrointestinal medicine.

[61]  Cong Wang,et al.  [Epithelioid hemangioendothelioma: a clinicopathologic analysis of 13 cases]. , 2015, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[62]  C. Antonescu,et al.  Thoracic Epithelioid Malignant Vascular Tumors: A Clinicopathologic Study of 52 Cases With Emphasis on Pathologic Grading and Molecular Studies of WWTR1-CAMTA1 Fusions , 2015, The American journal of surgical pathology.

[63]  Verónica Rivas,et al.  Role of G protein-coupled receptor kinase 2 in tumoral angiogenesis , 2014, Molecular & cellular oncology.

[64]  M. F. Petruzzelli,et al.  Epithelioid Hemangioendothelioma: An Overview and Update on a Rare Vascular Tumor , 2014, Oncology reviews.

[65]  Rodrigo Dienstmann,et al.  Standardized decision support in next generation sequencing reports of somatic cancer variants , 2014, Molecular oncology.

[66]  J. V. van Gorp,et al.  Epithelioid Hemangioendothelioma: clinicopathologic, immunhistochemical, and molecular genetic analysis of 39 cases , 2014, Diagnostic Pathology.

[67]  S. Pileri,et al.  Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma. , 2014, World journal of gastroenterology.

[68]  Jana Marie Schwarz,et al.  MutationTaster2: mutation prediction for the deep-sequencing age , 2014, Nature Methods.

[69]  J. Martina,et al.  Novel roles for the MiTF/TFE family of transcription factors in organelle biogenesis, nutrient sensing, and energy homeostasis , 2014, Cellular and Molecular Life Sciences.

[70]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[71]  M. Rubin,et al.  Novel YAP1‐TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma , 2013, Genes, chromosomes & cancer.

[72]  J. Blay,et al.  Sorafenib in patients with progressive epithelioid hemangioendothelioma , 2013, Cancer.

[73]  K. Guan,et al.  The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. , 2012, Seminars in cell & developmental biology.

[74]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[75]  Pablo Cingolani,et al.  © 2012 Landes Bioscience. Do not distribute. , 2022 .

[76]  A. Gabizon,et al.  Malignant epithelioid hemangioendothelioma of the liver successfully treated with pegylated liposomal doxorubicin. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  M. Gerstein,et al.  Identification of a Disease-Defining Gene Fusion in Epithelioid Hemangioendothelioma , 2011, Science Translational Medicine.

[78]  C. Antonescu,et al.  A novel WWTR1‐CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites , 2011, Genes, chromosomes & cancer.

[79]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[80]  A. Montag,et al.  Epithelioid Hemangioendothelioma of Soft Tissue: A Proposal for Risk Stratification Based on 49 Cases , 2008, The American journal of surgical pathology.

[81]  H. Friess,et al.  Primary malignant hepatic epithelioid hemangioendothelioma , 2006, Cancer.

[82]  K. Hiroshima,et al.  Risk factors and independent predictors of survival in patients with pulmonary epithelioid haemangioendothelioma. Review of the literature and a case report , 2006, Respirology.

[83]  A. Alomari.  The lollipop sign: a new cross-sectional sign of hepatic epithelioid hemangioendothelioma. , 2006, European journal of radiology.

[84]  B. O'Neil,et al.  Response of epithelioid haemangioendothelioma to liposomal doxorubicin. , 2005, The Lancet. Oncology.

[85]  S. Reed,et al.  hCDC4 gene mutations in endometrial cancer. , 2002, Cancer research.

[86]  R. Merion,et al.  Epithelioid hemangioendothelioma of the liver disseminated to the peritoneum treated with liver transplantation and interferon alpha-2B. , 2002, Transplantation.

[87]  L. Garbe,et al.  Aggressive form of pleural epithelioid haemangioendothelioma: complete response after chemotherapy. , 1999, The European respiratory journal.

[88]  K. Ishak,et al.  Epithelioid hemangioendothelioma of the liver , 1999, Cancer.

[89]  Katherine M Enzinger,et al.  Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma. , 1982, Cancer.

[90]  OUP accepted manuscript , 2022, Bioinformatics.

[91]  S. Broski,et al.  Epithelioid hemangioendothelioma: evaluation by 18F-FDG PET/CT. , 2021, American journal of nuclear medicine and molecular imaging.

[92]  M. von Mehren,et al.  An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.